A Priovant Therapeutics proof‑of‑concept study showed brepocitinib, a dual JAK1/TYK2 inhibitor licensed from Pfizer, met its goals in cutaneous sarcoidosis — a rare inflammatory skin disorder with no FDA‑approved treatments. The readout positions the molecule for pivotal testing and wider development under Roivant’s rare‑disease strategy. The result underscores continued industry interest in JAK/TYK2 modulation for inflammatory and rare indications. The study outcome increases the drug’s commercial potential and could accelerate regulatory planning and pivotal trial design for a category with unmet need.